Similar articles for PMID: 24105670

Year	Number of Results
2000	1
2001	1
2002	1
2004	3
2005	2
2007	1
2008	6
2009	4
2010	8
2011	12
2012	12
2013	10
2014	25
2015	9
2016	11
2017	10
2018	11
2019	5
2020	3
2021	2
2022	1
2024	0

1

Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.

Koeppen H, Rost S, Yauch RL. Koeppen H, et al. J Pathol. 2014 Jan;232(2):210-8. doi: 10.1002/path.4268. J Pathol. 2014. PMID: 24105670 Review.

2

The emerging role of MET/HGF inhibitors in oncology.

Scagliotti GV, Novello S, von Pawel J. Scagliotti GV, et al. Cancer Treat Rev. 2013 Nov;39(7):793-801. doi: 10.1016/j.ctrv.2013.02.001. Epub 2013 Feb 28. Cancer Treat Rev. 2013. PMID: 23453860 Review.

3

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Eder JP, et al. Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318488 Review.

4

Targeting the hepatocyte growth factor/Met pathway in cancer.

De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP. De Silva DM, et al. Biochem Soc Trans. 2017 Aug 15;45(4):855-870. doi: 10.1042/BST20160132. Epub 2017 Jul 3. Biochem Soc Trans. 2017. PMID: 28673936 Review.

5

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

Liu X, Newton RC, Scherle PA. Liu X, et al. Trends Mol Med. 2010 Jan;16(1):37-45. doi: 10.1016/j.molmed.2009.11.005. Epub 2009 Dec 22. Trends Mol Med. 2010. PMID: 20031486 Review.

6

C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.

Bahrami A, Shahidsales S, Khazaei M, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A. Bahrami A, et al. J Cell Physiol. 2017 Oct;232(10):2657-2673. doi: 10.1002/jcp.25794. Epub 2017 Apr 10. J Cell Physiol. 2017. PMID: 28075018 Review.

7

Progress in cancer therapy targeting c-Met signaling pathway.

Jung KH, Park BH, Hong SS. Jung KH, et al. Arch Pharm Res. 2012 Mar;35(4):595-604. doi: 10.1007/s12272-012-0402-6. Epub 2012 May 3. Arch Pharm Res. 2012. PMID: 22553051 Review.

8

c-Met targeting in advanced gastric cancer: An open challenge.

Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. Marano L, et al. Cancer Lett. 2015 Aug 28;365(1):30-6. doi: 10.1016/j.canlet.2015.05.028. Epub 2015 Jun 3. Cancer Lett. 2015. PMID: 26049023 Review.

9

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Comoglio PM, Giordano S, Trusolino L. Comoglio PM, et al. Nat Rev Drug Discov. 2008 Jun;7(6):504-16. doi: 10.1038/nrd2530. Nat Rev Drug Discov. 2008. PMID: 18511928 Review.

10

c-MET kinase inhibitors: a patent review (2011 - 2013).

Zhu K, Kong X, Zhao D, Liang Z, Luo C. Zhu K, et al. Expert Opin Ther Pat. 2014 Feb;24(2):217-30. doi: 10.1517/13543776.2014.864279. Epub 2013 Nov 25. Expert Opin Ther Pat. 2014. PMID: 24266843 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

121 results

Results by year